BPH 수술 치료 시장(-2030년) : 유형, 약제 유형, 치료, 최종 사용자 세계 예측(-2030년)
BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride)), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030
상품코드:1660146
리서치사:MarketsandMarkets
발행일:2025년 02월
페이지 정보:영문 329 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
BPH 수술 치료 시장 규모는 2024년 126억 2,000만 달러를 기록했습니다. 예측 기간 동안 CAGR 5.3%로 추이하고, 2030년에는 171억 9,000만 달러 규모에 달할 것으로 예측됩니다.
노인 남성 인구 증가는 세계 BPH 환자 증가의 원인이되었습니다. BPH는 연령과 관련이 있으며 노화는 BPH의 위험 요인으로 알려져 있습니다. 50세 이상의 남성의 약 50%, 70세 이상의 남성의 약 80%가 BPH의 영향하에 있습니다.
조사 범위
조사 대상 연도
2022-2030년
기준 연도
2023년
예측 기간
2024-2030년
검토 단위
금액(달러)
부문별
약제 유형, 유형, 치료, 최종 사용자별
대상 지역
북미, 유럽, 아시아태평양, 중동&아프리카
"약제 유형별로는 α차단제 부문이 2023년 최대 점유율을 보였다"
이것은 주로 알파 차단제가 BPH의 첫 번째 선택 치료제로 권장되기 때문입니다. 알파 차단제는 전립선과 방광 경부의 평활근을 이완시켜 요류를 개선하고 방광 출구 폐색을 줄입니다.
"아시아태평양이 예측 기간 동안 최대 성장률을 보여줄 전망"
이 지역의 BPH 수술 치료에 대한 수요는 주로 노인 인구 증가, 아시아 국가의 GDP 증가, 아시아태평양 국가의 의료 지출 증가, 사회적 인지도 증가로 인한 것입니다.
본 보고서에서는 세계 BPH 수술 치료 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 기술·특허 동향, 법규제 환경, 사례 연구, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
밸류체인 분석
공급망 분석
생태계 분석
Porter's Five Forces 분석
주요 이해관계자와 구매 기준
규제 시나리오
가격 분석
기술 분석
PESTLE 분석
특허 분석
무역 분석
주요 회의 및 이벤트
고객의 사업에 영향을 주는 동향/혁신
생성형 AI/AI가 BPH 수술 치료 시장에 미치는 영향
투자와 자금조달 시나리오
제6장 BPH 수술 치료 시장 : 약제 유형별
α차단제
5-α 환원 효소 억제제
기타
제7장 BPH 수술 치료 시장 : 유형별
전립선 경피적 절제술(TURP)
레이저 수술
UROLIFT 시술
REZUM 시술
로봇 지원 워터젯 절제
전립선 스텐트
경피적 마이크로 웨이브 열 치료(TUMT)
전립선 경피적 바늘 절제술(TUNA)
전립선 동맥 색전술(PAE)
기타
제8장 BPH 수술 치료 시장 : 치료법별
단제요법
병용 약제 요법
제9장 BPH 수술 치료 시장 : 최종 사용자별
병원
외래수술센터(ASC)와 클리닉
재택 케어
제10장 BPH 수술 치료 시장 : 지역별
북미
거시경제 전망
미국
캐나다
유럽
거시경제 전망
독일
영국
프랑스
이탈리아
스페인
기타
아시아태평양
거시경제 전망
일본
중국
인도
호주
기타
라틴아메리카
거시경제 전망
브라질
멕시코
기타
중동 및 아프리카
거시경제 전망
GCC 국가
거시경제 전망
제11장 경쟁 구도
개요
주요 진입기업의 전략/강점
수익 분석
시장 점유율 분석
기업평가 매트릭스 : 의약품 유형별 : 주요기업
기업 평가 매트릭스, 유형별 : 주요 기업
기업평가 매트릭스 : 스타트업/중소기업
기업평가와 재무지표
브랜드/제품 비교
경쟁 시나리오
제12장 기업 프로파일
주요 기업
GLAXOSMITHKLINE PLC
ELI LILLY AND COMPANY
TELEFLEX INCORPORATED
BOSTON SCIENTIFIC CORPORATION
PROCEPT BIOROBOTICS CORPORATION
ASTELLAS PHARMA INC.
ALEMBIC PHARMACEUTICALS LIMITED
ASAHI KASEI CORPORATION
ORGANON & CO.
OLYMPUS CORPORATION
COLOPLAST GROUP
IPG PHOTONICS CORPORATION
VIATRIS INC.
ABBVIE INC.
PROSTALUND AB
기타 기업
KARL STORZ SE & CO. KG
RICHARD WOLF GMBH
UNILAB, INC.
BIOLITEC HOLDING GMBH & CO KG
UROLOGIX, LLC.
ADVIN HEALTH CARE
MEDIFOCUS, INC.
JENASURGICAL(ASCLEPION LASER TECHNOLOGIES GMBH)
PNN MEDICAL A/S
SURGICAL LASERS INC.
QUANTA SYSTEM
ALLIUM LTD.
SRS MEDICAL
LABORIE MEDICAL TECHNOLOGIES
COOK MEDICAL
제13장 부록
KTH
영문 목차
영문목차
The global BPH surgical treatment market is valued at an estimated 12.62 billion in 2024 and is projected to reach USD 17.19 billion by 2030, at a CAGR of 5.3% during the forecast period. The growing elderly male population is leading to the cause of BPH patients globally. Therefore, BPH is related to age, and aging is known as a risk factor for BPH. Approximately 50% of men over the age of 50 and around 80% of men over the age of 70 are under the influence of BPH.
Scope of the Report
Years Considered for the Study
2022-2030
Base Year
2023
Forecast Period
2024-2030
Units Considered
Value (USD)
Segments
By Drug Type, By Type, Therapy, End User
Regions covered
North America, Europe, Asia Pacific, Latin America, and Middle East Africa
In 2023, the alpha-blockers segment accounted for the largest share of the BPH surgical treatment market, by drug type.
Alpha-blockers, 5-alpha reductase inhibitors, and other drug types make up the drug-type-based segments of the BPH surgical treatment market. Market share for BPH surgical treatment was highest in the Alpha-blockers in 2023. This is mainly due to the Alpha-blockers being recommended as first-line treatment for BPH. a-blockers relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.
"The home care settings segment is projected to witness the highest growth rate in BPH surgical treatment market, by the end-user, during the forecast period."
Based on end users, the BPH surgical treatment market is segmented into hospitals, ambulatory surgery centers & clinics, and home care settings. The driving factors that force home care settings to BPH surgical treatment is that the patients prefer taking medicine over surgery in most cases, which has supported the growth of this segment. Also, patients avoid surgical or minimally invasive procedures (e.g., TURP, laser therapy) due to potential complications, discomfort, or recovery time.
"The Asia Pacific region is projected to witness highest growth rate in the BPH surgical treatment market during the forecast period"
The global BPH surgical treatment market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Throughout the forecast period, the BPH surgical treatment market is expected to grow at the fastest rate in the Asia Pacific region. The demand for BPH surgical treatment in the APAC is mainly driven by the growing geriatric population, the increasing GDP of Asian countries, the rising healthcare expenditure in the APAC countries, and growing public awareness.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 - 50%, Tier 2 - 30%, and Tier 3 - 20%
By Designation: C-level - 25%, D-level - 20%, and Others - 55%
By Region: North America - 35%, Europe - 32%, Asia Pacific - 21%, Latin America - 8%, Middle East & Africa - 1%, and the GCC Countries - 3%
Lists of Companies Profiled in the Report:
GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy), Asclepion Laser Technologies GmbH (Germany), Cook Medical (US), SRS Medical (US), Pnn Medical A/S (Denmark), Allium Ltd. (Israel), Urologix, LLC (US), and Medifocus, Inc. (Canada).
Research Coverage:
In this report, the BPH surgical treatment market has been categorized based on drug type (alpha-blockers, 5-alpha reductase inhibitors, and other drug types), type (Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezum Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and others) end user (hospitals, ASCs & clinics, and home care settings), therapy (monotherapy and combination drug therapy), and region (Europe, Middle East & Africa, North America, Latin America, Asia Pacific, and the GCC Countries).
Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the BPH surgical treatment market's expansion is included in detail in this study. An exhaustive study of the key players in the cochlear implants market has been done to provide insights into their business profiles, products offered, noteworthy strategies, product launches, and approvals, and other recent activities pertaining to the market.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall BPH surgical treatment market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restraints.
The report provides insights on the following pointers:
Analysis of key drivers: (Expanding aging population and increasing prevalence of BPH, Rising cases of obesity in males, and Growing preference for minimally invasive surgeries), restraints (High cost of cochlear implants and associated surgeries and surgical risks, procedural complications, and long post-surgery rehabilitation), opportunities (Side effects associated with BPH medications and High cost of BPH surgical treatment), and challenges (Shortage of skilled professionals, Low awareness regarding prostate health and Product recalls) influencing the growth of the in BPH surgical treatment market.
Market Development: Comprehensive information about lucrative markets - the report analyses the BPH surgical treatment market across varied regions.
Product Development/Innovation: Comprehensive information about product development and new technologies - the report analyses the BPH surgical treatment market.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the BPH surgical treatment market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark) and IPG Photonics Corporation (Russia) in the BPH surgical treatment market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach, by type
2.2.1.2 Approach 1: Company revenue estimation approach, by drug type
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.4.1 STUDY ASSUMPTIONS
2.4.2 GROWTH RATE ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.5.1 METHODOLOGY-RELATED LIMITATIONS
2.5.2 SCOPE-RELATED LIMITATIONS
2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BPH SURGICAL TREATMENT MARKET OVERVIEW
4.2 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE AND COUNTRY (2024)
